Saroglitazar: Targeting Non-Alcoholic Steatohepatitis, a Potential US$35-40 Billion Market.
Nonalcoholic fatty liver disease (NAFLD), a disorder characterized by fatty changes (and fibrosis in later stages) is expected to affect about 20...
482 Views
MedTech as an Investment Theme
Medicine is changing. For hundreds of years, the key drivers of progress were biology and chemistry. Now they are data science and software.Big...
247 Views
Andrew on Tech: IOT Everywhere
The proliferation of IoT: With over 25% 5-year CAGR for IoT devices shipment and wafer foundry market but a very fragmented vendors list, we...
326 Views
New Long Position: 'Red Bull' like Immune Boost Against Cancer
Immune Design Corp (IMDZ US) is an emerging immuno-oncology company (based in Seattle, Washington) that is using its proprietary technology in...
329 Views
Contrarian Idea of the Day: Long Dynavax Technologies (DVAX US)
Dynavax Technologies (DVAX) common stock plunged today after receiving a complete response letter (CRL) from FDA regarding its approval...
292 Views